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The transformation of monocyte-derived macrophages into lipid-laden foam cells is one 
inflammatory process underlying atherosclerotic disease. Previous studies have demonstrated 
that fullerene derivatives (FDs) have inflammation-blunting properties. Thus, it was 
hypothesized that FD could inhibit the transformation process underlying foam cell formation. 
Fullerene derivatives inhibited the phorbol myristic acid/oxidized low-density lipoprotein-
induced differentiation of macrophages into foam cells as determined by lipid staining and 
morphology. Lipoprotein-induced generation of TNF-α, C5a-induced MC activation, ICAM-
1 driven adhesion, and CD36 expression were significantly inhibited in FD treated cells 
compared to non-treated cells. Inhibition appeared to be mediated through the NF-κB pathway as 
FD reduced expression of NF-κB and atherosclerosis-associated genes. Compared to controls, 
FD dramatically inhibited plaque formation in arteries of apolipoprotein E null mice. Thus, FD 
may be an unrecognized therapy to prevent atherosclerotic lesions via inhibition of foam cell 
formation and MC stabilization. 
 




Atherosclerotic disease begins when monocytes are exposed to oxidized low-density lipoprotein 
(ox-LDL) which form macrophage-derived foam cells that initiate plaque formation on blood 
vessels.1 The plaque can suddenly rupture and cause thrombosis; leading to myocardial 
infarction or stroke. Given the severe implications of this process, new strategies that inhibit 
this progression before it occurs would reduce patient mortality and morbidity. 
 
Mast cells (MC) are ubiquitously expressed in tissue and have been shown to be involved in 
the pathogenesis of atherosclerotic plaque buildup, erosion and rupture.2, 3 These cells are 
uniquely positioned to release their vast content of inflammatory mediators in and around 
affected vessels and into the circulation. Mast cells accumulate in human atherosclerotic 
lesions4 and chronic activation of MC in the atherosclerotic lesions may be a pre-disposing 
stimulus leading to plaque rupture.2 
 
The mechanisms leading to the transformation of monocytes into foam cells is complex, 
involving MC activation, oxidative stress, NF-κB activation, localized cytokine secretion, and 
the up-regulation of scavengerand cell adhesion receptors/ligands.5, 6 Thus, a therapy that would 
block macrophage-to-foam cell transformation, stabilize MC activation, and reduce MC noxious 
mediator secretion may serve as a platform for new treatment strategies aimed at preventing 
atherosclerosis. 
 
Fullerenes are carbon spheres that have a wide range of potentially beneficial biological 
properties. We recently showed that water soluble FDs are non-toxic7 and inhibit allergic,8, 9 
pulmonary, and dermatological inflammation.10 Previous studies examining the biodistribution 
of FD have shown them to be efficiently excreted from the body with negligible accumulation in 
major organs.11, 12, 13, 14, 15, 16 Our studies suggest that the anti-inflammatory effects of FD may be 
due to their ability to interfere with several molecules involved in NF-κB-mediated activation, 
cytokine secretion, and oxidative stress responses.9 Given the link between inflammation, 
oxidative stress, NF-κB activation and atherosclerosis, we hypothesized that FD could inhibit the 
underlying mechanisms of atherosclerosis and foam cell formation. We show that certain FDs 
inhibit foam cell formation and inflammatory mediator release associated with atherosclerosis 
through an NF-κB-dependent mechanism in vitro and can prevent the morbidity and mortality 






A panel of approximately 30 anti-inflammatory FDs9 were initially tested for their ability to 
inhibit foam cell formation in vitro. From this initial screen both amphiphilic liposomal 
malonylfullerene (ALM) and tris-malonate fullerene (C3) were chosen for further analysis. The 
FDs were bought from Luna Innovations and their formulation is described elsewhere.12, 17 
 
Generation of monocyte-derived macrophage foam cells 
 
Low-density lipoproteins from human plasma were oxidized as previously described to produce 
ox-LDL.18 To obtain macrophage-derived foam cells U937 monocytic cells (0.5-1.0 × 106 
cells/mL) were treated with 100 ng/mL phorbol myristilic acid (PMA) for 24 h and washed 1 
time with media, and ox-LDL (10 μg/mL) was added for 48 h as described previously.19 
Confirmation of macrophage and foam cell development was determined using surface markers 
to CD68, CD36, and oil red O staining (ORO), respectively (data not shown) as described.9, 20, 21 
Tumor necrosis factor α (TNF-α) levels were measured using a kit from Sigma. 
 
Scanning electron microscopy 
 
U937 cells were challenged with PMA as above, followed by FD (5 μg/mL) for 24 h before the 
addition of ox-LDL. Following treatment cells were fixed on an aluminum foil substrate, and 
dehydrated using a gradient of ethanol with increasing percentages of 60%, 70%, 80%, 90% and 
100% for 10 min, each. After air-drying, the foil substrate was mounted on standard Hitachi 
15mm aluminum specimen mount with standard double sided carbon tape. Images were obtained 
using a Hitachi S-4800 FESEM with a beam setting of 1.0 kV and 5.0 μA. 
 
Effect of FD on ICAM-1 and CD36 expression and NF-κB signaling intermediates 
 
U937 cells were treated with PMA and ox-LDL as above followed by various concentrations of 
FD for 24 h before the ox-LDL was added. Treated cells were subjected to FACs analysis with 
ICAM-1 and CD36 specific mouse antibodies (Santa Cruz) and FITC-conjugated anti-mouse 
antibodies. For Western blotting to examine concentration and time-dependent effects on 
macrophages signaling molecules, cells with or without FD treatment were lysed, subjected to 
SDS-PAGE, and probed with the indicated mouse anti-human antibodies as described 
previously.9, 20 As a negative control a non-specific mouse antibody was used in all experiments. 
 
Analysis of NF-κB pathway and related molecules by qPCR 
 
U937 cells were treated with PMA and ox-LDL as above followed by various concentrations of 
FD for 24 h before the ox-LDL was added. Total cellular RNA was extracted from FD treated or 
untreated cells as per manufacturer's protocol using the RNeasy® mini kit (Qiagen, Valencia, 
CA). Gene expression was determined using Applied Biosystems Human NF-κB TaqMan® 
Array Gene Signature Plates and TaqMan® RNA-to-CT™ 1-Step Kit (Life Technologies, 
Carlsbad, CA) using an Applied Biosystems 7500 Fast Real-Time PCR System. In addition, 
custom primers for ICAM-1, CCL2, NF-κB1, TRAF2, IKK-β and IL-8 were designed and 
purchased from Integrated DNA Technologies.6, 22 Experiments with the custom primer sets were 
performed using the AMV First Strand Synthesis Kit (New England Biolabs, Ipswich, MA) to 
produce cDNA followed by the SYBR® Premix Ex Taq™ II (Tli RNaseH Plus) (Takara, Japan) 
for the qPCR. Fold change in expression was obtained by the ΔΔCt method which gives a 
comparative analysis of gene expression between two samples. Briefly, to obtain the up- or 
down-regulation of those genes affected by FD, control cell RNA (no FD treatment) was probed 
with housekeeping and target-specific primers to establish a baseline expression. The RNA 
expression from cells treated with FD was then normalized to the controls in the non-treated 
cells. Data are presented as the fold change of expression between these two conditions. 
 
Human mast cell preparation and mediator release 
 
Mast cells from human skin and lung20, 23 were incubated with or without FD for 16 h at 37°C 
(optimal for cellular uptake).9, 24 The next day, cells were stimulated with 500 μg/mL C5a for 
30 min (degranulation) or overnight (cytokine production). TNF-α levels were measured as 
described above and degranulation was measured as previously described.9 
 
In vivo assessment of plaque formation 
 
Homozygous male B6.129P2 apolipoprotein E knockout (ApoE−/−) and wild-type C57BL/6J 
mice (n = 6/group) were treated by i.p. with ALM or C3(i.p. 5mg/kg/100 μL per injection) or fed 
ad libitum (2.5 μg/mL) in drinking water. There was no observed difference in the amount of 
water intake by the mice given control water (no FD) and mice given FD. Given an average 
water intake of 5.8mL/day, each mouse consumed approximately 14.5 μg (0.2 μg/g body weight) 
of FD each day. At day eight (after four injections) mice were fed a Teklad custom atherogenic 
rodent high fat diet (HFD; 02028) for up to nine weeks with FD or PBS injected every other day. 
Mice were maintained in a temperature and humidity-controlled room with a 12 hlight/dark cycle 
and were given free access to food and water. At week 10 mice were sacrificed and tissue sample 
was prepared as described10 and serum cholesterol, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), creatinine, and lactate dehydrogenase (LDH) levels were evaluated 







The size distribution profile of ALM and C3 was 0.251 μm and 0.117 μm, respectively while 
the zeta potentials were −59.02 mV and −95.50 mV, suggesting stability of FD in solution. The 
size distribution and zeta potential did not significantly change after vigorous vortexing or 
sonication. Nanosight nanoparticle tracking of ALM and C3 revealed a mean particle size of 
0.142 μm for ALM and 0.082 μm for C3. The smaller mean size from the Nanosight is a result of 
the individualized nature of particle size measurement. No cellular (U937 and THP-1) toxicity 
was observed with either FD when using up to 100 μg/mL (data not shown). 
 
Fullerene derivatives prevent morphological changes in PMA/ox-LDL-challenged cells 
 
Treating monocytes with PMA and ox-LDL induces their transformation into lipid-laden foam 
cells.25 SEM was used to examine the morphological changes associated with foam cell 
formation under these conditions with or without FD pre-incubation. As seen in Figure 1, A and 
B, untreated U937 cells have a relatively smooth plasma membrane with minor areas of surface 
irregularity and are spherical in shape. The addition of PMA/ox-LDL induces a drastic 
phenotypic change characterized by an amorphous shape, cellular elongation, and ruffling of the 
plasma membrane (Figure 1, C and D) as described previously.19 However, the addition of ALM 
prevented this phenotypic change in the U937 cells (Figure 1, E and F). Similar results were 
observed with C3 (data not shown). 
 
Fullerene derivative pre-incubation prevents cytokine release, foam cell formation, and cell 
adhesion 
 
Previous studies have shown that TNF-α release from activated monocytes induces foam cell 
formation.26 Given that FDs have been shown to prevent TNF-α release in other cell types,8, 9, 27 
we hypothesized that FD would also inhibit the production of TNF-α from 
monocytes/macrophages. To test this hypothesis, we examined the effects of ALM on TNF-α 
release from PMA activated U937 monocytes. As shown in Figure 2, A, cells were treated for 
24 h with PMA and ox-LDL, and those untreated with FD showed a significantly higher amount 
of TNF-α than FD treated U937 cells. However, when cells were pretreated with 5.0 μg/mL of 
FD for 24 h there was a statistically significant inhibition of TNF-α release, ranging from 58% to 
77%. Similar statistically significant inhibition of TNF-α release was seen with ALM and C3 
when levels were monitored at 12 h (data not shown). Thus, FD may inhibit foam cell formation 
through inhibition of TNF-α release. 
 
 
Figure 1. FDs prevent morphological changes associated with foam cell formation. U937 cells not treated with 
ALM (A, B) show the characteristic smooth plasma membrane and spherical shape of a monocyte. The PMA/ox-
LDL-challenged U937 cells transformed to foam cells exhibit amorphous shape, elongation, and roughing of the 
plasma membrane (C, D). However, when the PMA/ox-LDL-challenged U937 cells were treated with ALM 
(5 μg/mL), the phenotypic changes were prevented (E, F). 
 
 
Figure 2. (A) TNF-α release from U937 cells is inhibited by FD. U937 cells were incubated with PMA, 5 μg/mL 
FD [ALM (dark gray bars), C3 (light gray bars), or no FD (black bars)], and ox-LDL as described in Methods. Cells 
were centrifuged and supernatants assayed for TNF-α via ELISA. Significance (P < 0.05) indicated by an asterisk * 
was determined using the Student t test. Results are the average of three separate experiments, each done in 
triplicate. (B and C) Fullerene derivatives inhibit cell adhesion and lipid uptake in U937 cells. U937 cells were 
challenged with PMA (b, c) or without (a; negative control). PBS (b, vehicle control), or ALM (c; 10 μg/mL) was 
added followed by ox-LDL as described above. In the top panels cells in suspension were photographed for 
clumping while the lower panel cells were stained with ORO. Pictures of the cells in culture or after ORO staining 
were taken using an inverted microscope at 10× (top) or 40× (bottom) magnification. The graph represents the 
quantification of ORO staining. Results are representative of three separate experiments using both ALM and C3. 
All values with an * are significantly different compared to non-FD cells (P < 0.05). (D) Fullerene treatment 
prevents the up-regulation of ICAM-1 and CD36. U973 Cells (in duplicate) were treated with PMA, ox-LDL, 
followed by various concentrations of FD. Treated cells were assayed via FACS using antibodies against ICAM-1 
(a) and CD36 (b). The graph shows the average mean fluorescent intensity (MFI) of the signal (±SD) from three 
separate experiments. As a control MOPC was substituted for the primary antibodies and demonstrated no staining 
(not shown). All values with an * are significantly different compared to non-FD cells (P < 0.05). 
 
TNF-α activated monocytes initiate cellular clumping and lipid uptake as part of the foam cell 
formation process.28 PMA-treated cells showed significant clumping and ORO staining (Figure 
2, B; middle) consistent with previous studies.28 However, the ALM-treated cells showed no 
significant clumping or ORO staining (Figure 2, B; right) compared to non-treated U937 cells 
(Figure 2, B; left). In order to quantify the observations in Figure 1, Figure 2, B, the uptake of 
lipids was assessed. Quantification of the ORO staining demonstrated significant inhibition of 
lipid uptake in FD treated vs. untreated cells (Figure 1, C). 
 
The clumping induced by activated monocytes in atherogenesis is mediated through the up-
regulation of ICAM-1.28 We hypothesized that FD inhibited the clumping of activated 
monocytes through ICAM-1 inhibition. To test this hypothesis, we treated cells with PMA 
(100 ng/mL), ox-LDL (10 μg/mL), and varying concentrations of FD and examined for the up-
regulation of ICAM-1 using flow cytometry. As seen in Figure 2, D, the same FD treatment 
conditions that prevented cell clumping also prevented the up-regulation of ICAM-1, in a dose-
dependent manner. Although a trend can be observed, the data were not statistically significant. 
Thus, FD prevents activation-induced monocytic cell–cell adhesion possibly through the 
inhibition of ICAM-1. 
 
Up-regulation of CD36 scavenger receptors on foam cells is another key event in ox-LDL uptake 
and foam cell formation during atherosclerosis. We investigated the effect of ALM and C3 on 
CD36 receptor expression. As seen in Figure 2, D, CD36 receptor expression was downregulated 
with varying concentrations of both FD. Taken together, FDs inhibit several foam cell specific 
functional and phenotypic characteristics. 
 
Fullerene derivatives effects on atherosclerosis-associated RNA transcripts, protein expression, 
and NF-κB-signaling intermediates in foam cells 
 
Given the observation that TNF-α release was significantly inhibited by FD we focused our 
efforts on the NF-κB pathway using qPCR. As seen in Figure 3, A, ALM caused a significant 
reduction in several atherosclerosis-related intermediates including CCL2 (91% reduction), IL-8 
(90% reduction), VCAM (89% reduction), IL-1 (73% reduction), and TNFS15 (75% reduction). 
To further validate how FD affected these gene products, we performed more focused studies on 
several genes including TRAF2, ICAM1, IKBKB, CCL2, IL8, and NF-κB. As seen in Figure 3, 
B those genes that were observed to be downregulated by FD were again observed to be 
downregulated using separate primers thus validating those observations in Figure 3, A. 
 
NF-κB is involved in TNF-α induced foam cell formation,29 which involves the 
signal transducer TRAF230 and IκB kinase (IKK).31 Since both C3 and ALM appear to similarly 
inhibit foam cell formation, we chose ALM for the signaling studies. We hypothesized that ALM 
was inhibiting foam cell formation through the inhibition of the NF-κB pathway through RIP, 
IKK, TRAF, or Nf-κB1 intermediates. As seen in Figure 3, C/D, ALM/PMA/ox-LDL-treated 
U937 cells that were pretreated with ALM had a significant reduction of NF-κB1 and TRAF2 
expression at the protein level. This effect was dose (C) and time (D) dependent. The ALM-
mediated inhibition of NF-κB was maximal at two hours after ox-LDL challenge and total levels 
remained significantly lower at 16 h compared to non-ALM treated cells. Similar results were 
observed with TRAF2, however little expression or change was observed with other signaling 
intermediates involved in the NF-κB signaling pathway. Antibodies to detect phospho-IKK-α/β 
and IKK-α revealed a slight reduction in expression after two hours of ox-LDL treatment in 
ALM treated cells. Thus, ALM apparently inhibits the ox-LDL-induced increases in foam cell 
formation by affecting NF-κB1, TRAF2, and IKK proteins. 
 
Stabilization of human connective tissue mast cells by FD 
 
The complement system is activated in atherosclerosis32, 33 and patients with the disease have 
elevated serum levels of complement activationproducts (e.g., C5a).34 Mast cells are activated by 
complement byproductssuch as C5a,35 which may be one initiating or amplifying mechanism of 
atherosclerotic disease. As seen in Figure 4, human connective tissue MC pre-treated with ALM 




Figure 3. Fullerene derivatives effects on atherosclerosis-related mRNA transcripts 
in macrophages (A and B). U937 cells (in duplicate) were treated as above with PMA and ox-LDL with or without 
ALM (5 μg/mL). RNA was extracted via the RNeasy mini kit (Qiagen, Valencia CA) and qPCR was preformed 
using the Applied BiosystemsHuman NF-κB TaqMan® Array Gene Signature Plates per manufacturer's 
instructions. Values above the bars represent the percent downregulation of each gene as compared to non-treated 
cells and FD treated cells. Fullerene derivatives differentially affect NF-κB associated signaling intermediate 
proteins in a dose (C) and time (D) dependent manner. In panel (C) U937 cells treated with PMA followed by 
treatment with or without varying concentrations of FD and ox-LDL for 2 h. In panel (D) U937 cells treated with or 
without PMA followed by FD treatment and ox-LDL for 2 h or 16 h. Cells were lysed, subjected to SDS-PAGE, and 
Western blotted using the indicated antibodies as described previously.14 
 
Effect of FD derivatives on atherogenesis in vivo 
 
Given that FDs inhibit several underlying mechanisms leading to atherosclerosis in vitro, we 
hypothesized that they could prevent atherosclerosis in vivo. As seen in Figure 5, A, eighty 
percent of ApoE−/− mice fed a high HFD for ten weeks and injected with PBS did not survive. 
In contrast, the FD-treated mice appeared healthy, had no obvious abnormalities, and had 
weights similar to the age-matched WT mice (Figure 5, A). Upon further examination of 
the aortic arches, both ALM and C3 significantly reduced the size of the vessel-clogging plaque 
lesions (Figure 5, B). The non-treated, ApoE−/− mice had extremely large, vessel-blocking 
lesions in the aortic arch (Figure 5, C/D-arrows) that were virtually absent when mice were 
treated with FD (Figure 5, E-H) over the nine weeks. Thus, FDs prevent the plaque build-up 




Figure 4. Fullerenes reduce C5a-induced noxious mediator release from connective tissue mast cells. Mast cells 
were cultured with ALM or C3 at various concentrations, then washed and stimulated with C5a (500 μg/mL) for 
30 min for degranulation (A) or 16 h for TNF-α release (B). Cells were centrifuged and β-hexosaminidase release or 
TNF-α production was determined via ELISA. Data shown are means ± SE of triplicate samples that are 
representative of three separate experiments with separate MC cultures. All values with an * are significantly 
different compared to non-FD cells (P < 0.05). 
 
Fullerene derivatives prevent liver toxicity associated with HFD and do not affect kidney 
function 
 
Several toxicological markers in ALM and C3 treated mice were examined following 
administration via i.p. or oral administration. There were no morphological changes in the livers 
of ALM or C3-treated mice compared to ApoE−/− mice on HFD (data not shown). Serum 
cholesterol levels were significantly elevated in the non-FD treated animals fed an HFD 
compared to controls (P < 0.05). ALM and C3 did not affect total cholesterol, LDH, or AST 
levels (Figure 6, A, B, and E), but did reduce the HFD-induced elevations in creatinine and ALT 




Figure 5. Fullerenes derivatives prevent atherosclerosis in vivo. Mice were treated orally with 2.5 μg/mL FD and 
i.p. with 5 mg/kg/100 μL. After 10 weeks the percent of ApoE−/− or WT mice living was assessed (A). The aortas 
from ApoE−/− treated with PBS and fed an HFD, ApoE−/− treated with ALM or C3 plus HFD, were stained 
with hematoxylin and lesion sizes assessed as mean ± SD (B). Representative images of PBS treated (C, D), ALM 
oral (E, F), or C3 oral (G, H) are shown in the panel image. Note the large fatty streak lesions (arrows) in the PBS 
treated mice that are absent in the ALM or C3 treated mice. Pictures were taken using a 4× magnification. Pictures 
are representative of each of the six mice and were examined for each condition in a blinded fashion. All values with 




The aim of our study was to determine if FD could prevent the development of atherosclerosis 
based on the observation that certain FDs could attenuate other chronic inflammatory 
diseases.11, 36, 37 After initial testing of several FD, two were chosen for further studies based on 
their ability to inhibit foam cell formation in vitro. Monocyte U937 cells treated with FD had a 
significant decrease in total ORO staining under conditions that transform them into foam cells 
compared to untreated cells. Second, SEM analysis clearly demonstrated that drastic 
morphological changes that occur in PMA/ox-LDL challenged U937 cells are prevented with FD 
pre-incubation. Third, the clumping process, which occurs upon the monocyte-to-foam cell 
transformation,38 is prevented, possibly through the down-regulation of ICAM-1. Lastly, 
inflammatory mediator release from macrophages (TNF-α and MC-derived) leading to 
atherosclerosis was inhibited by FD. 
 
 
Figure 6. Fullerenes derivatives effect on in vivo toxicity. Mice (n = 6/group) were treated as described in Methods. 
After ten weeks, blood was collected from hearts of ApoE−/− mice fed an HFD and ApoE−/− treated via i.p. or oral 
(p.o.) administrations of ALM or C3 plus HFD. The total serum cholesterol (A), lactate 
dehydrogenase (B), creatinine (C), ALT (D), and AST (E) levels were measured in triplicate. 
 
Macrophages and MCs release a wide variety of inflammatory mediators involved in the 
initiation and progression of atherosclerosis including TNF-α which can upregulate ICAM-1.39 
Reducing serum levels of TNF-α improves patient outcomes.40 Our findings show that FDs 
inhibit the production of TNF-α up to 72% compared to non-treated cells and reduce cellular 
adhesion in U937 cells through reduction of CD11 expression. 
 
The CD36 receptor mediates the ox-LDL induction of atherogenic foam cells making it a 
therapeutic target for atherosclerosis.41 For example, cholesterol lowering statins significantly 
reduce CD36 receptor expression.42 Our results are similar as it is shown that FD can inhibit 
CD36 expression and thus interfere with a critical step involved in foam cells formation. 
 
Several studies have demonstrated that the induction of foam cell formation in atherosclerosis is 
mediated in part through oxidative stress,43For example, CD36 expression in monocytes is 
increased by oxidative stress.39, 44 Previous reports have proposed that membrane expression of 
CD36 involves redox signaling pathway via NADPH oxidase activation and the administration 
of antioxidants leads to a reduction in CD36 expression in monocytes derived from humans.44 
Given that certain FDs may possess anti-oxidant properties, these molecules may interfere in the 
progression of atherosclerotic disease at several levels. 
 
Furthermore, it has been demonstrated that oxidative stress influences the expression of NF-κB.45 
NF-κB is a key regulator of cell survival and proliferation and previous studies have shown that 
NF-κB inhibition reduces foam cell formation.46 TRAF2 is part of a group of adaptor proteins 
involved in signal transduction by most members of the TNF receptor family. TRAF2 has a key 
role in mediating TNFR1 induced activation of NF-κB.47 As seen in Figure 3, ALM was capable 
of dramatic reductions in TRAF2 and NF-κB expression in cells activated with ox-LDL. The 
activation of NF-κB via TRAF2 has been shown to increase foam cell formation.48 
 
Relatedly, we show for the first time that several atherosclerosis-related genes up-regulated in 
foam cells are dramatically inhibited in ALM-treated cells. For example, CCL2 is a chemokine 
found in the serum of hypercholesterolemic patients as well as atherosclerotic lesions.49 We 
found that ox-LDL/PMA caused a 40-fold induction in its cellular expression, which 
dramatically decreased in FD-treated cells. Similarly, ICAM-1 expression was dramatically 
reduced at both the gene (Figure 3) and protein levels (Figure 2) in foam cells. 
 
Mast cells have traditionally been associated with the initiation and proliferation of allergic 
responses, but a role for MC in atherosclerosis has now been clearly demonstrated.3 Mast cell 
numbers are greatly increased in the intima at sites of arterial plaque rupture,50 in advanced 
plaque lesions in the carotid artery,51 and in vulnerable plaque.52 Clinically, patients who died 
of acute myocardial infarction have an increased number of degranulated MCs at the site of 
plaque erosion or rupture.53Animal studies demonstrate that MC-deficient mice develop less 
atherosclerosis when fed an HFD compared to WT mice.54 The complement system is 
extensively activated in human atherosclerosis and lesions.32, 33 There also appears to be a 
positive correlation between serum levels of complement activation products (i.e., C5a) and 
human patients with atherosclerosis.34 Similar to other studies examining FD, inhibition of MC 
mediator release through IgE and non-IgE pathways,9, 37, 55 we show for the first time that human 
MC activation through C5a is also inhibited by FD. Thus, FD may not only affect foam cell 
formation but may also prevent atherosclerosis (via C5a stimulation) through the stabilization of 
MC and inhibition of the release of their noxious mediators. 
 
ALM and C3 demonstrated an almost complete inhibition of atherosclerotic plaque lesions in 
the aortic arches of ApoE−/− mice fed an HFD.The ALM and C3 treated groups showed 
significant inhibition of plaque lesions when compared to the PBS vehicle group. This inhibition 
of plaque lesions by the FD most likely explains the striking difference in survival rates between 
the two groups; 80% of the non-treated mice did not survive at the 10 week HFD regimen. None 
of the ALM-treated mice died in these studies. In both treated groups body weights did not 
change when compared to controls. Thus, rationally designed FD may represent a novel way for 
the prevention of complications associated with the accumulation and rupture of atherosclerotic 
plaque. 
 
The studies examining the toxicity of FD are still the subject of debate.56, 57, 58 Our studies using 
highly purified and well characterized FD support studies demonstrating a lack of toxicity.7, 59, 60 
Here, it is demonstrated that the two anti-atherogenic FDs are not toxic to the liver and kidney 
under the conditions tested. 
 
In conclusion, we have shown that certain FDs inhibit the formation of U937-derived foam cells 
possibly through the reduction of inflammatory cytokine release and adhesion molecule 
membrane expression through an NF-κB dependent mechanism. These compounds also 
significantly inhibit C5a-induced MC activation. The same FD also attenuated the accumulation 
of plaque lesions in vivo. These results further extend the utilization of FDs and suggest that they 
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